Dose standardization of botulinum toxin.
暂无分享,去创建一个
[1] M. Muenter,et al. Early cinematographic cases of postencephalitic parkinsonism and other movement disorders , 1998, Movement disorders : official journal of the Movement Disorder Society.
[2] C. Sampaio,et al. DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1 , 1997, Movement disorders : official journal of the Movement Disorder Society.
[3] K. Wohlfarth,et al. Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.
[4] M. Merello,et al. Sleep benefit in parkinson's disease , 1997, Movement disorders : official journal of the Movement Disorder Society.
[5] A. Braun,et al. Regional cerebral blood flow throughout the sleep-wake cycle. An H2(15)O PET study. , 1997, Brain : a journal of neurology.
[6] K. Wohlfarth,et al. Botulinum A toxins: units versus units , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[7] G. Plazzi,et al. Propriospinal myoclonus upon relaxation and drowsiness: A cause of severe insomnia , 1997, Movement disorders : official journal of the Movement Disorder Society.
[8] R. Benecke,et al. The EDB Test—A clinical test for the detection of antibodies to botulinum toxin type A , 1997 .
[9] R. Sloop,et al. Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use , 1997, Neurology.
[10] S. Sangla,et al. Dose standardisation of botulinum toxin. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[11] L. Pearce,et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. , 1995, Toxicon : official journal of the International Society on Toxinology.
[12] L. Pearce,et al. Measurement of botulinum toxin activity: evaluation of the lethality assay. , 1994, Toxicology and applied pharmacology.
[13] P. Hambleton,et al. Dose standardisation of botulinum toxin , 1994, The Lancet.
[14] M. Goodnough,et al. Stabilization of botulinum toxin type A during lyophilization , 1992, Applied and environmental microbiology.
[15] E. Schantz,et al. Dose standardisation of botulinum toxin , 1990, The Lancet.
[16] M. Hallett,et al. DOSE STANDARDISATION OF BOTULINUM TOXIN , 1989, The Lancet.
[17] J. Nutt,et al. Diurnal responsiveness to apomorphine , 1987, Neurology.
[18] B. Whaler,et al. Influence of nerve‐ending activity and of drugs on the rate of paralysis of rat diaphragm preparation by Cl. botulinum type A toxin , 1962, The Journal of physiology.
[19] E. Rüther,et al. Relationship between cerebral blood flow velocities and cerebral electrical activity in sleep. , 1994, Sleep.
[20] W. Koller,et al. Historical review: Abnormal movements associated with epidemic encephalitis lethargica , 1987, Movement disorders : official journal of the Movement Disorder Society.
[21] J. D. Parkes,et al. Fluctuations of disability in Parkinson's disease – clinical aspects , 1981 .
[22] D. Kautter,et al. Standardized Assay for Clostridium botulinum Toxins , 1978 .